MAP2 and delirium: However, treatment of cells with IL6 antibody during the differentiation stage prevented the reduction in neurogenesis (DCX, Map2) and increase in apoptosis (CC3) previously observed upon treatment with serum from delirium patients, when compared with serum from non-delirium patients (Time point 1, delirium vs delirium + IL6 antibody; for DCX, 19.1% vs 34.8%, p < 0.0001; for Map2, 25.1% vs 40.7%, p < 0.0001; for CC3, 17.3% vs 3.4%, p < 0.0001).